Uses of polymerase chain reaction in leukemia: detection of minimal residual disease and identification of novel genetic mutations.

[1]  J. Wang,et al.  Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. , 1992, Journal of molecular biology.

[2]  M. Slovak,et al.  Persistence of bcr-able gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase. , 1991, Transplantation.

[3]  G. Morgan,et al.  Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. , 1991, Blood.

[4]  B. Lange,et al.  Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment. , 1990, The New England journal of medicine.

[5]  M. Vidaud,et al.  Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia. , 1990, Leukemia.

[6]  C. Sawyers,et al.  Significance of residual leukaemia transcripts after bone marrow transplant for CML , 1990, The Lancet.

[7]  C. Sawyers,et al.  Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Kurzrock,et al.  Update on therapeutic options for chronic myelogenous leukemia. , 1990, Seminars in hematology.

[9]  J. Gabert,et al.  DETECTION OF RESIDUAL bcr/abl TRANSLOCATION BY POLYMERASE CHAIN REACTION IN CHRONIC MYELOID LEUKAEMIA PATIENTS AFTER BONE-MARROW TRANSPLANTATION , 1989, The Lancet.

[10]  D. Ginsburg,et al.  Detection of Philadelphia chromosome-positive cells by the polymerase chain reaction following bone marrow transplant for chronic myelogenous leukemia , 1989 .

[11]  B. Lange,et al.  Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Kantarjian,et al.  Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction. , 1989, Blood.

[13]  S. Kwok,et al.  Avoiding false positives with PCR , 1989, Nature.

[14]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.

[15]  H. Kantarjian,et al.  Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction. , 1988, Blood.

[16]  S. Smith,et al.  Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[17]  E J Freireich,et al.  Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. , 1987, Science.

[18]  H. Kantarjian,et al.  Clinical investigation of human alpha interferon in chronic myelogenous leukemia. , 1987, Blood.

[19]  B. Andersson,et al.  Development and characterization of a human myelogenous leukemia cell line resistant to 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide. , 1987, Cancer research.

[20]  Bruce A. Roe,et al.  Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene , 1986, Cell.

[21]  H. Deeg,et al.  Marrow transplantation for the treatment of chronic myelogenous leukemia. , 1986, Annals of internal medicine.

[22]  K. Mullis,et al.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. , 1985, Science.

[23]  W. Ross.  DNA topoisomerases as targets for cancer therapy. , 1985, Biochemical pharmacology.

[24]  E. Gehan,et al.  Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. , 1985, Blood.

[25]  Kees Stam,et al.  Structural organization of the bcr gene and its role in the Ph′ translocation , 1985, Nature.

[26]  L. Liu,et al.  Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.

[27]  J. Stephenson,et al.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22 , 1984, Cell.

[28]  J. Stephenson,et al.  Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia , 1983, Nature.

[29]  Goldman Jm,et al.  New approaches in chronic granulocytic leukemia--origin, prognosis, and treatment. , 1982 .

[30]  G. Canellos,et al.  Chronic granulocytic leukemia. , 1976, The Medical clinics of North America.

[31]  J. Sokal.  Evaluation of survival data for chronic myelocytic leukemia , 1976, American journal of hematology.

[32]  J. Rowley.  A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining , 1973, Nature.

[33]  R. Hetherington.  Teaching behavioural science. , 1969, Lancet.